KW 3902

Suppliers

Names

[ CAS No. ]:
136199-02-5

[ Name ]:
KW 3902

[Synonym ]:
KW 3902
MK-7418
1,3-Dnax

Chemical & Physical Properties

[ Density]:
1.262g/cm3

[ Boiling Point ]:
578ºC at 760mmHg

[ Molecular Formula ]:
C20H28N4O2

[ Molecular Weight ]:
356.46200

[ Flash Point ]:
303.4ºC

[ Exact Mass ]:
356.22100

[ PSA ]:
72.68000

[ LogP ]:
2.78400

[ Vapour Pressure ]:
2.33E-13mmHg at 25°C

[ Index of Refraction ]:
1.605

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Statements ]:
H413

[ RIDADR ]:
NONH for all modes of transport

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

  • 5,6-Diamino-1,3-dipropyluracil
  • 3-noradamantanecarboxylic acid
  • 2,5-Methanopentalene-3a(1H)-carbonyl chloride, hexahydro- (9CI)
  • 6-Amino-1,3-dipropyl-5-nitrosouracil

DownStream

Articles

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.

Am. J. Ther. 17(1) , 53-60, (2010)

Rolofylline is a potent, selective adenosine A1 receptor antagonist that was under development for the treatment of patients with acute decompensated heart failure and renal function impairment. This ...

The disconnect between phase II and phase III trials of drugs for heart failure.

Nat. Rev. Cardiol. 10(2) , 85-97, (2013)

Hospitalization for heart failure (HF) is a clinical entity associated with high postdischarge morbidity and mortality, yet few therapies are available to improve outcomes in patients with this condit...

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.

J. Card. Fail. 16(1) , 25-35, (2010)

Current treatment for acute decompensated heart failure (ADHF) is associated with incomplete resolution of symptoms and signs, recurrent symptoms of heart failure in-hospital and after discharge and h...


More Articles

Related Compounds

  • KW-2449
  • (2S)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4H-thieno[3,2-c][1]benzothiepin-9-yl)propanamide
  • KW-6055
  • KW-8232
  • sodium,(11E)-11-[2-(5,6-dimethylbenzimidazol-1-yl)ethylidene]-6H-benzo[c][1]benzoxepine-2-carboxylate
  • 6H-Pyrazolo(4,5,1-de)acridin-6-one,5-((3-aminopropyl)amino)-7,10-dihydroxy-2-(((2-hydroxyethyl)amino)methyl)-,dihydrochloride
  • 3-(5-Bromo-3-nitropyridin-2-yl)-1,2-oxazol-5-amine
  • 7-[(benzyloxy)carbonyl]-4-chloro-5-hydroxy-5H,6H,7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid
  • 1-{1-[(benzyloxy)carbonyl]piperidin-4-yl}-1H-1,2,3-triazole-5-carboxylic acid
  • 2-(5-Bromo-2-methoxypyridin-3-yl)ethanethioamide
  • rac-(1R,3S)-3-(1-{[(benzyloxy)carbonyl]amino}ethyl)-2,2-dimethylcyclobutane-1-carboxylic acid
  • rac-(2R,4R)-1-[(benzyloxy)carbonyl]-4-methyl-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
  • Methyl 5-(1-aminocyclopropyl)-2-methylfuran-3-carboxylate
  • rac-(2R,4R)-1-{[(9H-fluoren-9-yl)methoxy]carbonyl}-4-methyl-1,2,3,4-tetrahydroquinoline-2-carboxylic acid
  • Ethyl 2-(1-aminocyclopropyl)benzoate
  • 5-(Diethylamino)-2-(1-hydroxyprop-2-en-1-yl)phenol